Revenue Breakdown
Composition ()
No data
Revenue Streams
Halozyme Therapeutics Inc (HALO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 66.6% of total sales, equivalent to $236.04M. Other significant revenue streams include Sales of proprietary products and Sales of bulk rHuPH20. Understanding this composition is critical for investors evaluating how HALO navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Halozyme Therapeutics Inc maintains a gross margin of 79.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 61.51%, while the net margin is 49.46%. These profitability ratios, combined with a Return on Equity (ROE) of 124.50%, provide a clear picture of how effectively HALO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HALO competes directly with industry leaders such as KRYS and ARWR. With a market capitalization of $8.51B, it holds a significant position in the sector. When comparing efficiency, HALO's gross margin of 79.39% stands against KRYS's 95.64% and ARWR's 100.00%. Such benchmarking helps identify whether Halozyme Therapeutics Inc is trading at a premium or discount relative to its financial performance.
